Anthropometrics and prostate cancer risk

American Journal of Epidemiology

Volumn 165, Issue 11, 2007, Pages 1271-1279

  Littman, Alyson J ^a,b,c   White, Emily ^a,b   Kristal, Alan R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Seattle ERIC   (United States)

Author keywords

Body height; Body mass index; Body weight; Body weight changes; Cohort studies; Longitudinal studies; Prostatic neoplasms

Indexed keywords

CANCER; HEALTH RISK; OBESITY; RISK FACTOR; TUMOR;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; CANCER CLASSIFICATION; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HEIGHT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PROSTATE CANCER; RISK ASSESSMENT; BODY HEIGHT; BODY WEIGHT; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE TUMOR; RISK FACTOR; UNITED STATES; WEIGHT GAIN;

NORTH AMERICA; UNITED STATES; WASHINGTON [UNITED STATES];

AGED; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; HUMANS; MALE; MIDDLE AGED; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; WASHINGTON; WEIGHT GAIN;

EID: 34447282814     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm013     Document Type: Article

References (61)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.
2. Flegal KM. Epidemiologic aspects of overweight and obesity in the United States. Physiol Behav 2005;86:599-602.
3. Presti JC Jr. Obesity and prostate cancer. Curr Opin Urol 2005;15:13-16.
4. Amling CL. Relationship between obesity and prostate cancer. Curr Opin Urol 2005;15:167-71.
5. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
6. Nomura AM. Body size and prostate cancer. Epidemiol Rev 2001;23:126-31.
7. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006;17:5-9.
8. White E, Patterson RE, Kristal AR, et al. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 2004;159:83-93.
9. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998;68:899-917.
10. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
11. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
12. Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York, NY: Wiley, 1999.
13. Li CI, Malone KE, White E, et al. Age when maximum height is reached as a risk factor for breast cancer among young U.S. women. Epidemiology 1997;8:559-65.
14. Li CI, Stanford JL, Daling JR. Anthropometric variables in relation to risk of breast cancer in middle-aged women. Int J Epidemiol 2000;29:208-13.
15. Hayes RB, de Jong FH, Raatgever J, et al. Physical characteristics and factors related to sexual development and behaviour and the risk for prostatic cancer. Eur J Cancer Prev 1992;1:239-45.
16. Dagnelie PC, Schuurman AG, Goldbohm RA, et al. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 2004;93:1139-50.
17. Gunnell D, Okasha M, Smith GD, et al. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 2001;23:313-42.
18. Giles GG, Severi G, English DR, et al. Early growth, adult body size and prostate cancer risk. Int J Cancer 2003;103:241-5.
19. Kaaks R, Lukanova A, Rinaldi S, et al. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003;12:309-15.
20. Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000;3:157-72.
21. Macinnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003.
22. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997;89:385-9.
23. MacInnis RJ, English DR, Gertig DM, et al. Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:1417-21.
24. Rodriguez C, Patel AV, Calle EE, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10:345-53.
25. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
26. Pasquali R, Casimirri F, Cantobelli S, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991;40:101-4.
27. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22:439-45.
28. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:446-53.
29. Giovannucci E, Rimm EB, Stampfer MJ, et al. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997;6:557-63.
30. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977-83.
31. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95:1240-4.
32. Robinson WR, Stevens J, Gammon MD, et al. Obesity before age 30 years and risk of advanced prostate cancer. Am J Epidemiol 2005;161:1107-14.
33. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate 2005;62:316-21.
34. Bradbury BD, Wilk JB, Kaye JA. Obesity and the risk of prostate cancer (United States). Cancer Causes Control 2005; 16:637-41.
35. Schuurman AG, Goldbohm RA, Dorant E, et al. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 2000;151:541-9.
36. Dal Maso L, Zucchetto A, La Vecchia C, et al. Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br J Cancer 2004;90:2176-80.
37. Cerhan JR, Torner JC, Lynch CF, et al. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997;8:229-38.
38. Whittemore AS, Paffenbarger RS Jr, Anderson K, et al. Early precursors of site-specific cancers in college men and women. J Natl Cancer Inst 1985;74:43-51.
39. Friedenreich CM, McGregor SE, Courneya KS, et al. Case-control study of anthropometric measures and prostate cancer risk. Int J Cancer 2004;110:278-83.
40. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000;27:39-66.
41. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418-24.
42. Severi G, Morris HA, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86-91.
43. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003;12:1410-16.
44. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14:1262-9.
45. Cunha GR, Hayward SW, Wang YZ, et al. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107:1-10.
46. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
47. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-35.
48. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001;85:991-6.
49. Ribeiro R, Lopes C, Medeiros R. The link between obesity and prostate cancer: the leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 2006;9:19-24.
50. Meyer F, Bairati I, Shadmani R, et al. Dietary fat and prostate cancer survival. Cancer Causes Control 1999;10:245-51.
51. Kristal AR, Cohen JH, Qu P, et al. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:719-25.
52. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152-60.
53. Barqawi AB, Golden BK, O'Donnell C, et al. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 2005;65:708-12.
54. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005;103:1092-5.
55. Dahle SE, Chokkalingam AP, Gao YT, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599-604.
56. Freedland SJ, Platz EA, Presti JC Jr, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006;175:500-4; discussion 504.
57. Rimm EB, Stampfer MJ, Colditz GA, et al. Validity of selfreported waist and hip circumferences in men and women. Epidemiology 1990;1:466-73.
58. Engstrom JL, Paterson SA, Doherty A, et al. Accuracy of self-reported height and weight in women: an integrative review of the literature. J Midwifery Womens Health 2003;48:338-45.
59. Olivarius NF, Andreasen AH, Loken J. Accuracy of 1-, 5- and 10-year body weight recall given in a standard questionnaire. Int J Obes Relat Metab Disord 1997;21:67-71.
60. Tamakoshi K, Yatsuya H, Kondo T, et al. The accuracy of long-term recall of past body weight in Japanese adult men. Int J Obes Relat Metab Disord 2003;27:247-52.
61. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.